Provectus Pharmaceutical Analyst Coverage Continued by Small Cap Street

NEW YORK, Sept. 8, 2014 /PRNewswire/ -- Provectus Pharmaceutical, Inc. (AMEX: PVCT) – Small Cap Street continues coverage of PVCT. Melanoma that occurs on the skin, or cutaneous melanoma, is the most common type of melanoma.  According to the American Cancer Society, more than 120,000 new cases of melanoma are diagnosed in the U.S. each year.  The New England Journal of Medicine reports that the outlook for patients with advanced cutaneous melanoma is grim, with a 5-year survival rate of less than 10 percent of those diagnosed.

Provectus Pharmaceutical, Inc. is a development-stage pharmaceutical company that is primarily engaged in developing, licensing, and marketing two ethical prescription drug candidates, PV-10 and PH-10. The Company is developing PV-10 for treatment of several life threatening cancers, including advanced cutaneous melanoma, liver cancer, and breast cancer.

A brief analyst report on PVCT that includes recent events and the stock's technical outlook can be viewed by using the following link at no cost:

http://bit.ly/-PVCT-AnalystCoverage

Copy and paste to browser may be required.

About Small Cap Street

Once you read our reports written by our team of financial analysts you will understand that we make every effort to provide informative equity research reports for interested parties at no cost.

Our Financial Analysts spend countless hours researching stocks. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges. These reports include a straightforward assessment of the company by a financial analyst who has pledged to remain free of influence when writing research reports.

Forward-Looking Disclaimer  

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.  

Compliance Procedure  

Content is researched, written and reviewed on a best-effort basis. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the full analyst report.

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected]. For any urgent concerns or inquiries please contact us at [email protected].

Contact: [email protected], 810-715-9806

SOURCE Small Cap Street